South Dakota
CNS clinical trials in South Dakota
11 CNS studies are recruiting participants at sites in 4 cities across South Dakota as of November 16, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every South Dakota city with a recruiting study
By research area: Parkinson's Disease (6), Depression (3), Epilepsy (1), Migraine (1).
Sioux Falls (10), Rapid City (2), Pine Ridge (1), Yankton (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Depression: recently updated in South Dakota
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Lakota Family Acceptance Project Pilot RCT
- No phase
- Ages 13 and older
- All sexes
- Sponsor
- University of Michigan
- Recruiting in
- Pine Ridge · Rapid City
- Registry record
- NCT07865858 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Recruiting in
- Rapid City · Sioux Falls
- Registry record
- NCT06748222 · updated
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Recruiting in
- Sioux Falls
- Registry record
- NCT07412756 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in South Dakota on ClinicalTrials.gov.
Parkinson's disease: recently updated in South Dakota
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Recruiting in
- Sioux Falls
- Registry record
- NCT06989112 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Sioux Falls · Yankton
- Registry record
- NCT06966700 · updated
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Sioux Falls
- Registry record
- NCT07252739 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Sioux Falls
- Registry record
- NCT07174310 · updated
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Sioux Falls
- Registry record
- NCT04165070 · updated
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Sioux Falls
- Registry record
- NCT04165798 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in South Dakota on ClinicalTrials.gov.
Epilepsy: recently updated in South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
- Observational
- All ages
- All sexes
- Sponsor
- Sanford Health
- Recruiting in
- Sioux Falls
- Registry record
- NCT01793168 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in South Dakota on ClinicalTrials.gov.
Migraine: recently updated in South Dakota
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- Pfizer
- Recruiting in
- Sioux Falls
- Registry record
- NCT05156398 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in South Dakota on ClinicalTrials.gov.
Ask about studies in South Dakota
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections